688739.SHG Liaoning Chengda Biotechnology Co. Ltd. A
- Market cap
- CNY 8.67B
- P/E
- 130.2x
- P/B
- 0.93x
- ROE
- 0.7%
- Dividend yield
- 3.80%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688739.SHG undervalued?
Graham number688739.SHG trades 131.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Liaoning Chengda Biotechnology Co. Ltd. A fundamental analysis
No fundamental analysis for Liaoning Chengda Biotechnology Co. Ltd. A yet.
Liaoning Chengda Biotechnology Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Liaoning Chengda Biotechnology Co. Ltd. A
Liaoning Chengda Biotechnology Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of vaccines in China and internationally. It offers inactivated Japanese encephalitis and SPEEDA-rabies vaccines. The company also develops rabies vaccine which is in new drug approval stage; influenza vaccine which is in new drug application stage; recombinant human papillomavirus 15-valent vaccine which is in Phase II clinical stage; and 13-vale…
Full company profileLiaoning Chengda Biotechnology Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Liaoning Chengda Biotechnology Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.68B | 2.00B | 2.09B | 1.81B | 1.75B | 1.68B | 1.39B | 1.35B |
| Gross Profit | 1.44B | 1.72B | 1.88B | 1.58B | 1.46B | 1.39B | 1.10B | 1.01B |
| Operating Income | 787M | 988M | 1.03B | 778M | 593M | 454M | 197M | 177M |
| EBITDA | 855M | 1.06B | 1.15B | 961M | 703M | 577M | 350M | 110M |
| Net Income | 698M | 918M | 892M | 714M | 466M | 343M | 132M | 66.6M |
| EPS | 1.86 | 2.45 | 2.14 | 1.71 | 1.12 | 0.82 | 0.32 | 0.16 |
| Balance Sheet | ||||||||
| Total Assets | 3.74B | 4.51B | 9.79B | 10.1B | 10.1B | 10.1B | 9.75B | 9.70B |
| Total Liabilities | 311M | 390M | 441M | 406M | 482M | 489M | 392M | 356M |
| Shareholders' Equity | 3.42B | 4.12B | 9.35B | 9.65B | 9.60B | 9.56B | 9.35B | 9.34B |
| Cash & Short-term Investments | 1.25B | 985M | 2.83B | 5.80B | 4.55B | 4.50B | 4.36B | 3.59B |
| Cash Flow | ||||||||
| Operating Cash Flow | 724M | 860M | 506M | 546M | 677M | 501M | 341M | - |
| Capital Expenditure | 462M | 188M | 508M | 512M | 552M | 362M | 308M | 175M |
| Free Cash Flow | 262M | 671M | -1.97M | 34.9M | 125M | 138M | 32.8M | -33.6M |
| Ratios | ||||||||
| ROE | 20.4% | 22.3% | 9.5% | 7.4% | 4.9% | 3.6% | 1.4% | 0.7% |
| ROA | 18.7% | 20.4% | 9.1% | 7.1% | 4.6% | 3.4% | 1.4% | 0.7% |
| Net Profit Margin | 41.6% | 46.0% | 42.7% | 39.3% | 26.6% | 20.5% | 9.5% | 4.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Liaoning Chengda Biotechnology Co. Ltd. A dividends
- Dividend yield
- 3.80%
- Forward dividend
- 0.10 CNY
- Payout ratio
- 249.8%
- Ex-dividend date
- Jun 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 329M | 0.79 | 249.8% |
| 2024 | CNY 329M | 0.79 | 96.1% |
| 2023 | CNY 416M | 1.00 | 89.4% |
| 2022 | CNY 416M | 1.00 | 58.3% |
| 2021 | - | - | - |
| 2020 | CNY 225M | 0.60 | 24.5% |
| 2019 | CNY 225M | 0.60 | 32.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Liaoning Chengda Biotechnology Co. Ltd. A
- Insiders 57.57%
- Institutions 0.54%
- Public & others 41.89%
- Shares outstanding 416M
- Free float 169M
Liaoning Chengda Biotechnology Co. Ltd. A company profile
- Company name
- Liaoning Chengda Biotechnology Co. Ltd. A
- Ticker
- 688739.SHG
- ISIN
- CNE100004ZP2
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,781
- Fiscal year end
- December
- Address
- No. 1, Xinfang Street, Shenyang, China, 110179
- Phone
- 86 24 2378 9706
- Website
- cdbio.cn
About Liaoning Chengda Biotechnology Co. Ltd. A
Liaoning Chengda Biotechnology Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of vaccines in China and internationally. It offers inactivated Japanese encephalitis and SPEEDA-rabies vaccines. The company also develops rabies vaccine which is in new drug approval stage; influenza vaccine which is in new drug application stage; recombinant human papillomavirus 15-valent vaccine which is in Phase II clinical stage; and 13-valent pneumococcal polysaccharide conjugate, varicella, and meningococcal A, C, Y and W-135 conjugate vaccines which are in Phase I clinical stage. In addition, it is involved in the development of high-dose influenzae vaccine which is in CT approval stage; and vaccines in pre-clinical study stage, including 20-valent pneumococcal polysaccharide conjugate, recombinant zoster, multivalent HFMD, serogroup B meningococcal outer membrane vesicle, and rabies monoclonal antibody. The company was formerly known as Liaoning Chengda Biological Technology Limited Company and changed its name to Liaoning Chengda Biotechnology Co., Ltd. in November 2010. Liaoning Chengda Biotechnology Co., Ltd. was incorporated in 2002 and is headquartered in Shenyang, China. The company operates as a subsidiary of Liaoning Cheng Da Co., Ltd.
Liaoning Chengda Biotechnology Co. Ltd. A management
10- Mr. Yu MaoGM & Director · born 1980
- Mr. Jianwei CuiDeputy GM, CFO & Accounting Supervisor · born 1978
- Mr. Weiqiang SunDeputy GM & Chief Scientist · born 1960
- Mr. Junwei YangDeputy GM & Employee Director · born 1975
- Mr. Huanyu WangDeputy General Manager · born 1974
- Mr. Yeji LiBoard Secretary · born 1992
- Mr. Xin ChenDeputy General Manager · born 1971
- Mr. Deming YuanDeputy General Manager · born 1973
- Mr. Xu LiCore Technical Personnel · born 1973
- Ms. Yin ChenCore Technical Personnel · born 1985